| Krista J Sarvis, PHARMD | |
|
113 Comanche Rd, Fort Meade, SD 57741-1002 | |
| (605) 347-7000 | |
| Not Available |
| Full Name | Krista J Sarvis |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 113 Comanche Rd, Fort Meade, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245414499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 3174 (Wyoming) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Krista J Sarvis, PHARMD 113 Comanche Rd, Fort Meade, SD 57741-1002 Ph: (605) 347-7000 | Krista J Sarvis, PHARMD 113 Comanche Rd, Fort Meade, SD 57741-1002 Ph: (605) 347-7000 |
News Archive
In a new study, scientists at the University of Copenhagen show that a specific type of carbohydrate plays an important role in the intercellular signalling that controls the growth and development of the nervous system. In particular, defects in that carbohydrate may result in the uninhibited cell growth that characterizes the genetic disease neurofibromatosis and certain types of cancer.
In a paper published today in a special physical activity series of The Lancet, the Coordinated Approach to Child Health program developed by researchers at The University of Texas Health Science Center at Houston was identified as an excellent example of an evidence-based physical activity intervention that has been successfully scaled up to affect population health.
The presence of myopia, or nearsightedness, significantly affects the muscles used in focusing the lens of the eye-a finding with important implications for the development of "accommodating" implanted intraocular lenses (IOLs) that can adjust to different visual distances, reports a study in the January issue of Optometry and Vision Science, official journal of the American Academy of Optometry.
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
› Verified 9 days ago
Kaitlin Bottelberghe, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 113 Comanche Rd, Fort Meade, SD 57741 Phone: 605-347-2511 | |
Jessica A Mitchell, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 113 Comanche Rd, Fort Meade, SD 57741 Phone: 307-941-0023 | |
Dr. Megan Czmowski, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 113 Comanche Rd, Fort Meade, SD 57741 Phone: 605-347-2511 | |
Nathan Graves, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 113 Comanche Rd, Fort Meade, SD 57741 Phone: 605-347-2511 | |
Dr. Michael David Lemon, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 113 Comanche Rd, Fort Meade, SD 57741 Phone: 605-720-7107 Fax: 605-347-7207 | |
Whitney Rae Hutchison, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 113 Comanche Rd, Fort Meade, SD 57741 Phone: 605-347-2511 Fax: 612-725-1330 |